Subsequently, we made a pairwise comparison among them and it was of great interest to find that patients with HR+/HER2+ tumor had a favorable prognosis in both the whole MIBC population and MIBC patients without node macrometastasis, which was not the population that standard anti‐HER2 therapy was recommended for. The gene discussed is ERBB2; the disease is neoplasm.